🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Advanced Solid Tumor, Adult

A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors NCT07414836Phase 118 sites📍 Boston📍 St Louis📍 Hackensack BeOne Medicines · Tests: BG-C0979, Tislelizumab An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors NCT07222267Phase 132 sites📍 Birmingham📍 New Haven📍 St Louis BeOne Medicines · Tests: BG-75202, CDK4 Inhibitor, Estrogen Receptor Antagonist, Aromatase Inhibitor ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) NCT06415487Phase 19 sites📍 San Diego📍 Denver📍 Nashville Acepodia Biotech, Inc. · Tests: Cyclophosphamide, Fludarabine, ACE2016, Pembrolizumab COAST Therapy in Advanced Solid Tumors and Prostate Cancer NCT05036226Phase 1, Phase 21 site📍 Charleston Medical University of South Carolina · Tests: Hydroxychloroquine, Metformin, Sirolimus, Hydroxychloroquine, Metformin, Sirolimus, Dasatanib, Hydroxychloroquine, Metf… Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies NCT04282044Phase 13 sites📍 Scottsdale📍 La Jolla📍 Stanford BioEclipse Therapeutics · Tests: CRX100 suspension for infusion, Fludarabine, Cyclophosphamide Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma NCT07627698Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410Phase 138 sites📍 Phoenix📍 Tucson📍 Los Angeles Kura Oncology, Inc. · Tests: Darlifarnib, Cabozantinib, Adagrasib A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement NCT07359820Phase 219 sites📍 Phoenix📍 Jacksonville📍 Tampa Elevar Therapeutics · Tests: Lirafugratinib A Study of GC203 TIL in Advanced Solid Tumors (NF) NCT07256756Phase 11 site📍 Shenzhen Shanghai Juncell Therapeutics · Tests: GC203 TIL A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors NCT07361562Phase 115 sites📍 Scottsdale📍 Scottsdale📍 New Haven Cogent Biosciences, Inc. · Tests: CGT4255 Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors NCT04165772Phase 210 sites📍 Hartford📍 Miami📍 Basking Ridge Memorial Sloan Kettering Cancer Center · Tests: TSR-042 or Dostarlimab, capecitabine or 5-FU, Intensity Modulated Radiation Therapy (IMRT) A Study of PHST001 in Advanced Solid Tumors NCT06840886Phase 120 sites📍 Beverly Hills📍 Los Angeles📍 Palo Alto Pheast Therapeutics · Tests: PHST001, Paclitaxel, Topotecan, Doxorubicin, FOLFIRI Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors NCT06840821Phase 1, Phase 21 site📍 Jinan Mainline Biosciences (Shanghai) Co., Ltd · Tests: MB0151 for injection Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors NCT06770764Phase 11 site📍 Scottsdale Trutino Biosciences Inc. · Tests: ODC-IL2 A Study of TY-2699a in Patients With Locally Advanced or Metastatic Solid Tumors NCT05866692Phase 12 sites📍 Beijing📍 Jinan TYK Medicines, Inc · Tests: TY-2699a Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites📍 Scottsdale📍 Bethesda📍 Columbus Novartis Pharmaceuticals · Tests: dabrafenib, trametinib A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors NCT06131840Phase 148 sites📍 Phoenix📍 Scottsdale📍 Duarte Seagen, a wholly owned subsidiary of Pfizer · Tests: PF-08046050, bevacizumab, 5-Fluorouracil (5-FU), Oxaliplatin, Leucovorin (LV) Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) NCT07432295Phase 26 sites📍 Goodyear📍 Duarte📍 Boston I-Mab Biopharma US Limited · Tests: Givastomig, Nivolumab, 5Fluorouracil, Leucovorin, Oxaliplatin Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981Phase 17 sites📍 Detroit📍 St Louis📍 Canton Sairopa B.V. · Tests: ADU-1805, Pembrolizumab PIN in Combination With Anti-PD1 in Previously Treated Solid Tumor NCT06883149Phase 11 site📍 Beijing Chinese PLA General Hospital · Tests: PIN +anti-PD1 HF158K1 in Patients With HER-2 Expressing Advanced Solid Tumors NCT05861895Phase 12 sites📍 Dallas📍 Guangzhou HighField Biopharmaceuticals Corporation · Tests: HF158K1 / 1.4 g lipid dose, HF158K1 / 2.2 g lipid dose, HF158K1 / 2.9 g lipid dose IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors NCT04842812Phase 11 site📍 Guangzhou Second Affiliated Hospital of Guangzhou Medical University · Tests: TILs and CAR-TILs targeting HER2, Mesothelin, PSCA, MUC1, Lewis-Y, GPC3, AXL, EGFR, Claudin18.2/6, ROR1, GD1, or B7-H3 A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation NCT06778863Phase 121 sites📍 Scottsdale📍 Tucson📍 Los Angeles Clasp Therapeutics, Inc. · Tests: CLSP-1025 A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 ) NCT07417189Phase 1, Phase 21 site📍 Shanghai Abbisko Therapeutics Co, Ltd · Tests: ABSK141-400mg, ABSK141-Recommended Dose for Expansion (RDE), ABSK141-800mg, ABSK141-1200mg, ABSK141-Recommended Phase 2… A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors NCT07383506Phase 112 sites📍 Scottsdale📍 Los Angeles📍 Palo Alto Cogent Biosciences, Inc. · Tests: CGT6297 A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors NCT07715747Phase 11 site📍 Shanghai TJ Biopharma Co., Ltd. · Tests: TJ037130 Tiragolumab and Atezolizumab in Advanced Pan-cancer Patients NCT06003621Phase 213 sites📍 Albury📍 Albury📍 Coffs Harbour Omico · Tests: Tiragolumab, Atezolizumab DBC-664 in Adult Patients With Solid Tumors NCT07705035Phase 16 sites📍 Denver📍 Grand Rapids📍 East Brunswick Duboce Biopharmaceuticals, Inc. · Tests: DBC-664 A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors NCT07488676Phase 1, Phase 221 sites📍 Birmingham📍 Los Angeles📍 Miami Astellas Pharma Global Development, Inc. · Tests: ASP546C
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy